Chemical inhibitors of Cml3 can exert their inhibitory effects through various mechanisms, each interacting with distinct signaling pathways or cellular processes that are involved in the regulation of Cml3 activity. Staurosporine, for example, is a potent protein kinase inhibitor that can prevent the phosphorylation events necessary for the activation of Cml3. Similarly, Bisindolylmaleimide I targets Protein Kinase C, which is known to regulate a multitude of cellular functions, including those that govern the activity of Cml3, thereby inhibiting its function. The phosphoinositide 3-kinases (PI3Ks) are critical for numerous cellular processes, and their inhibition by LY294002 and Wortmannin can lead to the downregulation of the Akt signaling pathway, which in turn can inhibit Cml3 activity. This is because the Akt pathway is a major regulator of various proteins, including Cml3.
Furthermore, Rapamycin directly inhibits the mammalian target of rapamycin (mTOR), a central molecule in cell growth and metabolism that can have downstream effects on Cml3 activity by altering protein synthesis and turnover. In the context of the MAP kinase pathway, SB203580 and PD98059 specifically inhibit p38 MAP kinase and MEK respectively. Since p38 MAP kinase and MEK are integral components of the MAPK pathway that can regulate Cml3, their inhibition directly results in the reduction of Cml3 activity. U0126 is another MEK inhibitor which prevents the MAPK/ERK pathway from activating, leading to the inhibition of Cml3. SP600125 targets JNK, another kinase within the MAPK pathway, and its inhibition disrupts the signaling cascade that can activate Cml3. Src family kinases, which are upstream regulators in various signaling pathways, can be inhibited by PP2 and Dasatinib, leading to a decrease in Cml3 activity. Lastly, Y-27632 inhibits the Rho-associated protein kinase (ROCK), which can control cellular architecture and motility, processes that can indirectly regulate Cml3 activity, ultimately leading to its inhibition. Through these diverse mechanisms, each chemical can contribute to the functional inhibition of Cml3, demonstrating the complexity of cellular regulation and the multiple points at which it can be modulated.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinases which could be involved in the phosphorylation of Cml3, thus inhibiting its activation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I inhibits Protein Kinase C which could play a role in the signaling pathways regulating Cml3 activity, leading to its inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K which is involved in the Akt signaling pathway, a pathway that regulates Cml3 activity, resulting in its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that would inhibit the Akt pathway, thereby inhibiting Cml3 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that could be involved in the regulation of Cml3 through protein synthesis and turnover. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which might be part of the MAPK pathway that regulates Cml3, thereby inhibiting Cml3. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is involved in the MAPK/ERK pathway that regulates Cml3 activity, leading to inhibition of Cml3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that would prevent the activation of the MAPK/ERK pathway, inhibiting Cml3 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, part of the MAPK pathway, which would inhibit signaling pathways regulating Cml3 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 inhibits Src family kinases, which are upstream regulators that could control signaling pathways involving Cml3 leading to its inhibition. | ||||||